ONGOING STUDIES

• IELSG47 Study4 October 2019
  MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
• IELSG46 Study1 June 2019
  Integrated molecular and clinical profiling to optimize outcome prediction in Splenic Marginal Zone Lymphoma
• IELSG45 Study30 May 2019
  Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial)

LATEST NEWSLETTER

• Newsletter Number 5224 February 2020
  Click here to open pdf file

PUBLICATIONS

• MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial1 February 2021
  Lancet Haematol 2021; 8: e110-21. Authors: Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JCE, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K, for the International Extranodal Lymphoma Study Group (IELSG)
• Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment26 October 2020
  Haematologica. 2020 Jan 2. pii: haematol.2019.237990. doi: 10.3324/haematol.2019.237990. Epub 2020 Jan 2. Authors: Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson PW, Zucca E.